ANSELL LIMITED (ANN)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

ANN - ANSELL LIMITED

Year End: June
GICS Industry Group : Health Care Equipment & Services
Index: ASX100 | ASX200 | ASX300 | ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$40.50

28 Oct
2020

0.180

OPEN

$39.71

0.45%

HIGH

$40.59

0

LOW

$39.61

TARGET
$39.766 -1.8% downside
Franking for last dividend paid out: 0%
OTHER COMPANIES IN THE SAME SECTOR
ASB . LGD . SRV . KPG . AIM . CUP . QHL .
MARKET CONSENSUS FORECAST
ANN: 1
Title FY21
Forecast
FY22
Forecast
EPS (cps) 195.2 xxx
DPS (cps) 84.2 xxx
EPS Growth N/A xxx
DPS Growth N/A xxx
PE Ratio 20.7 xxx
Dividend Yield 2.1% xxx
Div Pay Ratio(%) 43.1% xxx
This company reports in USD.
All estimates have been converted into AUD by FNArena at present FX values.

Dividend yield today if purchased 3 years ago: 2.10%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

1.24

Estimated Dividend Growth
(Average Of Past Three Years)

 %

Amount Invested

Tell Me The Dividend After This Many Years

Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 31/08 - 41.16c (0%)

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.2

No. Of Recommendations

7
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Citi

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

xx/xx/xxxx

5

xxxxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Credit Suisse

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgan Stanley

16/10/2020

1

Overweight

$43.50

7.41%

Ansell's FY20 healthcare sales saw organic growth of 13.8% to US$895m. Assuming the first nine months were at the lower end of the organic growth range at 3%, this implies June quarter organic growth of circa 40%, comments the broker.

Annualising the June quarter run rate suggests about 36% growth in healthcare revenue in FY21, which Morgan Stanley considers conservative.

The company highlighted covid-19 has changed behaviours which are driving increased personal protective equipment (PPE) usage with new worker categories starting to use PPE.

Morgan Stanley expects healthcare growth to outstrip industrial growth in the near-term. Overweight rating. Target is unchanged at $43.50. Industry view is In-Line.

FORECAST
Morgan Stanley forecasts a full year FY21 dividend of 81.71 cents and EPS of 196.13 cents.
Morgan Stanley forecasts a full year FY22 dividend of 88.31 cents and EPS of 211.97 cents.

Ord Minnett

xx/xx/xxxx

2

xxxxxxx xx xxxxxxxxxx xxxx xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

UBS

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgans

xx/xx/xxxx

3

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

ANN STOCK CHART